Systemic effects of chronic obstructive pulmonary disease

Expert Review of Respiratory Medicine

Volumn 1, Issue 1, 2007, Pages 75-84

  Halpin, David mg ^a  

^a ROYAL DEVON AND EXETER HOSPITAL   (United Kingdom)

Author keywords

cardiovascular disease; COPD; inflammation; skeletal muscle dysfunction; systemic effect; weight loss

Indexed keywords

EID: 79952079069     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/17476348.1.1.75     Document Type: Article

References (152)

1. Samet JM. Definitions and methodology in COPD research. In: Clinical Epidemiology of Chronic Obstructive Pulmonary Disease. Hensley MJ, Saunders NA, (Eds). Marcel Dekker, NY, USA 1–22 (1989)
2. Miller MR. Chronic obstructive pulmonary disease and ‘150 years of blowing’. Hosp. Med. 59 (9), 719–722 (1998).
3. Ciba Foundation Guest Symposium. Terminology, definitions and classification of chronic obstructive pulmonary emphysema and related conditions. Thorax 14, 286–299 (1959).
4. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur. Respir. J. 23 (6), 932–946 (2004).
5. Hogg JC, Chu F, Utokaparch S et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N. Engl. J. Med. 350 (26), 2645–2653 (2004).
6. Agusti AG, Noguera A, Sauleda J, Sala E, Pons J, Busquets X. Systemic effects of chronic obstructive pulmonary disease. Eur. Respir. J. 21 (2), 347–360 (2003).
7. Agusti A, Thomas A. Neff lecture. Chronic obstructive pulmonary disease: a systemic disease. Proc. Am. Thorac. Soc. 3 (6), 478–481 (2006).
8. Gan WQ, Man SF, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 59 (7), 574–580 (2004).
9. De Torres JP, Cordoba-Lanus E, Lopez-Aguilar CA et al. C-reactive protein levels and clinically important predictive outcomes in stable COPD patients. Eur. Respir. J. 27 (5), 902–907 (2006).
10. Rahman I, Morrison D, Donaldson K, MacNee W. Systemic oxidative stress in asthma, COPD, and smokers. Am. J. Respir. Crit. Care Med. 154 (4 Pt 1), 1055–1060 (1996).
11. Pratico D, Basili S, Vieri M, Cordova C, Violi F, Fitzgerald GA. Chronic obstructive pulmonary disease is associated with an increase in urinary levels of isoprostane F2α-III, an index of oxidant stress. Am. J. Respir. Crit. Care Med. 158 (6), 1709–1714 (1998).
12. Noguera A, Batle S, Miralles C et al. Enhanced neutrophil response in chronic obstructive pulmonary disease. Thorax 56 (6), 432–437 (2001).
13. Noguera A, Busquets X, Sauleda J, Villaverde JM, MacNee W, Agusti AG. Expression of adhesion molecules and G proteins in circulating neutrophils in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 158 (5 Pt 1), 1664–1668 (1998).
14. Wedzicha JA, Seemungal TA, MacCallum PK et al. Acute exacerbations of chronic obstructive pulmonary disease are accompanied by elevations of plasma fibrinogen and serum IL-6 levels. J. Thromb. Haemost. 84 (2), 210–215 (2000).
15. Seemungal T, Harper-Owen R, Bhowmik A et al. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 164 (9), 1618–1623 (2001).
16. Dentener MA, Creutzberg EC, Schols AM et al. Systemic anti-inflammatory mediators in COPD: increase in soluble interleukin 1 receptor II during treatment of exacerbations. Thorax 56 (9), 721–726 (2001).
17. Agusti A, MacNee W, Donaldson K, Cosio M. Hypothesis: does COPD have an autoimmune component? Thorax 58 (10), 832–834 (2003).
18. Jones NL, Killian KJ. Exercise limitation in health and disease. N. Engl. J. Med. 343 (9), 632–641 (2000).
19. Killian KJ, Leblanc P, Martin DH, Summers E, Jones NL, Campbell EJ. Exercise capacity and ventilatory, circulatory, and symptom limitation in patients with chronic airflow limitation. Am. Rev. Respir. Dis. 146 (4), 935–940 (1992).
20. Skeletal muscle dysfunction in chronic obstructive pulmonary disease. A statement of the American Thoracic Society and European Respiratory Society. Am. J. Respir. Crit. Care Med. 159 (4 Pt 2), S1 –S40 (1999).
21. Coronell C, Orozco-Levi M, Mendez R, Ramirez-Sarmiento A, Galdiz JB, Gea J. Relevance of assessing quadriceps endurance in patients with COPD. Eur. Respir. J. 24 (1), 129–136 (2004).
22. Allaire J, Maltais F, Doyon JF et al. Peripheral muscle endurance and the oxidative profile of the quadriceps in patients with COPD. Thorax 59 (8), 673–678 (2004).
23. Hul AV, Harlaar J, Gosselink R, Hollander P, Postmus P, Kwakkel G. Quadriceps muscle endurance in patients with chronic obstructive pulmonary disease. Muscle Nerve 29 (2), 267–274 (2004).
24. Bernard S, LeBlanc P, Whittom F et al. Peripheral muscle weakness in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 158 (2), 629–634 (1998).
25. Houmard JA, Weidner ML, Gavigan KE, Tyndall GL, Hickey MS, Alshami A. Fiber type and citrate synthase activity in the human gastrocnemius and vastus lateralis with aging. J. Appl. Physiol. 85 (4), 1337–1341 (1998).
26. 2 with small muscle mass exercise. Am. J. Respir. Crit. Care Med. 169 (1), 89–96 (2004).
27. Couillard A, Maltais F, Saey D et al. Exercise-induced quadriceps oxidative stress and peripheral muscle dysfunction in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 167 (12), 1664–1669 (2003).
28. Gosker HR, van Mameren H, van Dijk PJ et al. Skeletal muscle fibre-type shifting and metabolic profile in patients with chronic obstructive pulmonary disease. Eur. Respir. J. 19 (4), 617–625 (2002).
29. Sala E, Roca J, Marrades RM et al. Effects of endurance training on skeletal muscle bioenergetics in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 159 (6), 1726–1734 (1999).
30. Maltais F, LeBlanc P, Simard C et al. Skeletal muscle adaptation to endurance training in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 154 (2 Pt 1), 442–447 (1996).
31. Maltais F, LeBlanc P, Jobin J et al. Intensity of training and physiologic adaptation in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 155 (2), 555–561 (1997).
32. Bigard AX, Sanchez H, Birot O, Serrurier B. Myosin heavy chain composition of skeletal muscles in young rats growing under hypobaric hypoxia conditions. J. Appl. Physiol. 88 (2), 479–486 (2000).
33. Green HJ, Sutton JR, Cymerman A, Young PM, Houston CS. Operation Everest II: adaptations in human skeletal muscle. J. Appl. Physiol. 66 (5), 2454–2461 (1989).
34. Bigard AX, Brunet A, Guezennec CY, Monod H. Skeletal muscle changes after endurance training at high altitude. J. Appl. Physiol. 71 (6), 2114–2121 (1991).
35. Hughes RL, Katz H, Sahgal V, Campbell JA, Hartz R, Shields TW. Fiber size and energy metabolites in five separate muscles from patients with chronic obstructive lung diseases. Respiration 44 (5), 321–328 (1983).
36. Jakobsson P, Jorfeldt L, Brundin A. Skeletal muscle metabolites and fibre types in patients with advanced chronic obstructive pulmonary disease (COPD, with and without chronic respiratory failure. Eur. Respir. J. 3 (2), 192–196 (1990).
37. Decramer M, Stas KJ. Corticosteroid-induced myopathy involving respiratory muscles in patients with chronic obstructive pulmonary disease or asthma. Am. Rev. Respir. Dis. 146 (3), 800–802 (1992).
38. Decramer M, Lacquet LM, Fagard R, Rogiers P. Corticosteroids contribute to muscle weakness in chronic airflow obstruction. Am. J. Respir. Crit. Care Med. 150 (1), 11–16 (1994).
39. Hopkinson NS, Man WD, Dayer MJ et al. Acute effect of oral steroids on muscle function in chronic obstructive pulmonary disease. Eur. Respir. J. 24 (1), 137–142 (2004).
40. Whittom F, Jobin J, Simard PM et al. Histochemical and morphological characteristics of the vastus lateralis muscle in patients with chronic obstructive pulmonary disease. Med. Sci. Sports Exerc. 30 (10), 1467–1474 (1998).
41. Maltais F, Simard AA, Simard C, Jobin J, Desgagnes P, LeBlanc P. Oxidative capacity of the skeletal muscle and lactic acid kinetics during exercise in normal subjects and in patients with COPD. Am. J. Respir. Crit. Care Med. 153 (1), 288–293 (1996).
42. Eid AA, Ionescu AA, Nixon LS et al. Inflammatory response and body composition in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 164 (8 Pt 1), 1414–1418 (2001).
43. Di Francia M, Barbier D, Mege JL, Orehek J. Tumor necrosis factor-α levels and weight loss in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 150 (5 Pt 1), 1453–1455 (1994).
44. Schols AM, Buurman WA, Staal van den Brekel AJ, Dentener MA, Wouters EF. Evidence for a relation between metabolic derangements and increased levels of inflammatory mediators in a subgroup of patients with chronic obstructive pulmonary disease. Thorax 51 (8), 819–824 (1996).
45. Li YP, Schwartz RJ, Waddell ID, Holloway BR, Reid MB. Skeletal muscle myocytes undergo protein loss and reactive oxygen-mediated NF-κB activation in response to tumor necrosis factor α. FASEB J. 12 (10), 871–880 (1998).
46. Llovera M, Garcia-Martinez C, Agell N, Lopez-Soriano FJ, Argiles JM. TNF can directly induce the expression of ubiquitin-dependent proteolytic system in rat soleus muscles. Biochem. Biophys. Res. Commun. 230 (2), 238–241 (1997).
47. Mitch WE, Goldberg AL. Mechanisms of muscle wasting. The role of the ubiquitin–proteasome pathway. N. Engl. J. Med. 335 (25), 1897–1905 (1996).
48. Wouters EF. Chronic obstructive pulmonary disease. 5: systemic effects of COPD. Thorax 57 (12), 1067–1070 (2002).
49. Agusti AG, Sauleda J, Miralles C et al. Skeletal muscle apoptosis and weight loss in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 166 (4), 485–489 (2002).
50. Baker SJ, Reddy EP. Modulation of life and death by the TNF receptor superfamily. Oncogene 17 (25), 3261–3270 (1998).
51. Reid MB, Lannergren J, Westerblad H. Respiratory and limb muscle weakness induced by tumor necrosis factor-α: involvement of muscle myofilaments. Am. J. Respir. Crit. Care Med. 166 (4), 479–484 (2002).
52. Boots AW, Haenen GR, Bast A. Oxidant metabolism in chronic obstructive pulmonary disease. Eur. Respir. J. (Suppl. 46), S14 –S27 (2003).
53. Couillard A, Prefaut C. From muscle disuse to myopathy in COPD: potential contribution of oxidative stress. Eur. Respir. J. 26 (4), 703–719 (2005).
54. Levine S, Kaiser L, Leferovich J, Tikunov B. Cellular adaptations in the diaphragm in chronic obstructive pulmonary disease. N. Engl. J. Med. 337 (25), 1799–1806 (1997).
55. Baumann H, Jaggi M, Soland F, Howald H, Schaub MC. Exercise training induces transitions of myosin isoform subunits within histochemically typed human muscle fibres. Pflugers Arch. 409 (4–5), 349–360 (1987).
56. Howald H, Hoppeler H, Claassen H, Mathieu O, Straub R. Influences of endurance training on the ultrastructural composition of the different muscle fiber types in humans. Pflugers Arch. 403 (4), 369–376 (1985).
57. Sauleda J, Gea J, Orozco-Levi M et al. Structure and function relationships of the respiratory muscles. Eur. Respir. J. 11 (4), 906–911 (1998).
58. Bellemare F, Grassino A. Force reserve of the diaphragm in patients with chronic obstructive pulmonary disease. J. Appl. Physiol. 55 (1 Pt 1), 8–15 (1983).
59. Ottenheijm CA, Heunks LM, Li Y et al. Activation of the ubiquitin-proteasome pathway in the diaphragm in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 174 (9), 997–1002 (2006).
60. National Institute for Clinical Excellence (NICE). Chronic obstructive pulmonary disease. National clinical guideline for management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax 59 (Suppl. 1), 1–232 (2004).
61. Schols AM, Slangen J, Volovics L, Wouters EF. Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 157 (6 Pt 1), 1791–1797 (1998).
62. Landbo C, Prescott E, Lange P, Vestbo J, Almdal TP. Prognostic value of nutritional status in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 160 (6), 1856–1861 (1999).
63. Vestbo J, Prescott E, Almdal T et al. Body mass, fat-free body mass, and prognosis in patients with chronic obstructive pulmonary disease from a random population sample: findings from the copenhagen city heart study. Am. J. Respir. Crit. Care Med. 173 (1), 79–83 (2006).
64. Schols AM, Soeters PB, Mostert R, Saris WH, Wouters EF. Energy balance in chronic obstructive pulmonary disease. Am. Rev. Respir. Dis. 143 (6), 1248–1252 (1991).
65. Schols AM, Wouters EF. Nutritional abnormalities and supplementation in chronic obstructive pulmonary disease. Clin. Chest Med. 21 (4), 753–762 (2000).
66. Schols AM, Soeters PB, Dingemans AM, Mostert R, Frantzen PJ, Wouters EF. Prevalence and characteristics of nutritional depletion in patients with stable COPD eligible for pulmonary rehabilitation. Am. Rev. Respir. Dis. 147 (5), 1151–1156 (1993).
67. Engelen MP, Wouters EF, Deutz NE, Does JD, Schols AM. Effects of exercise on amino acid metabolism in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 163 (4), 859–864 (2001).
68. Engelen MP, Schols AM, Does JD, Gosker HR, Deutz NE, Wouters EF. Exercise-induced lactate increase in relation to muscle substrates in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 162 (5), 1697–1704 (2000).
69. Engelen MP, Schols AM, Lamers RJ, Wouters EF. Different patterns of chronic tissue wasting among patients with chronic obstructive pulmonary disease. Clin. Nutr. 18 (5), 275–280 (1999).
70. Ferreira IM, Brooks D, Lacasse Y, Goldstein RS. Nutritional support for individuals with COPD: a meta-analysis. Chest 117 (3), 672–678 (2000).
71. Schols AM, Fredrix EW, Soeters PB, Westerterp KR, Wouters EF. Resting energy expenditure in patients with chronic obstructive pulmonary disease. Am. J. Clin. Nutr. 54 (6), 983–987 (1991).
72. Baarends EM, Schols AM, Westerterp KR, Wouters EF. Total daily energy expenditure relative to resting energy expenditure in clinically stable patients with COPD. Thorax 52 (9), 780–785 (1997).
73. Hugli O, Schutz Y, Fitting JW. The daily energy expenditure in stable chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 153 (1), 294–300 (1996).
74. Baarends EM, Schols AM, Slebos DJ, Mostert R, Janssen PP, Wouters EF. Metabolic and ventilatory response pattern to arm elevation in patients with COPD and healthy age-matched subjects. Eur. Respir. J. 8 (8), 1345–1351 (1995).
75. Amoroso P, Wilson SR, Moxham J, Ponte J. Acute effects of inhaled salbutamol on the metabolic rate of normal subjects. Thorax 48 (9), 882–885 (1993).
76. Sridhar MK. Why do patients with emphysema lose weight? Lancet 345 (8959), 1190–1191 (1995).
77. De Godoy I, Donahoe M, Calhoun WJ, Mancino J, Rogers RM. Elevated TNF-α production by peripheral blood monocytes of weight-losing COPD patients. Am. J. Respir. Crit. Care Med. 153 (2), 633–637 (1996).
78. Nguyen LT, Bedu M, Caillaud D et al. Increased resting energy expenditure is related to plasma TNF-α concentration in stable COPD patients. Clin. Nutr. 18 (5), 269–274 (1999).
79. Auwerx J, Staels B. Leptin. Lancet 351 (9104), 737–742 (1998).
80. Schols AM, Creutzberg EC, Buurman WA, Campfield LA, Saris WH, Wouters EF. Plasma leptin is related to proinflammatory status and dietary intake in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 160 (4), 1220–1226 (1999).
81. Creutzberg EC, Wouters EF, Vanderhoven-Augustin IM, Dentener MA, Schols AM. Disturbances in leptin metabolism are related to energy imbalance during acute exacerbations of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 162 (4 Pt 1), 1239–1245 (2000).
82. Calverley PM, Anderson JA, Celli B et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med. 356 (8), 775–789 (2007).
83. Higgins MW, Keller JB. Predictors of mortality in the adult population of Tecumseh. Arch. Environ. Health 21 (3), 418–424 (1970).
84. Hole DJ, Watt GC, Davey-Smith G, Hart CL, Gillis CR, Hawthorne VM. Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study. Br. Med. J. 313 (7059), 711–715; discussion 715–716 (1996).
85. Stavem K, Aaser E, Sandvik L et al. Lung function, smoking and mortality in a 26-year follow-up of healthy middle-aged males. Eur. Respir. J. 25 (4), 618–625 (2005).
86. Schroeder EB, Welch VL, Couper D et al. Lung function and incident coronary heart disease: the Atherosclerosis Risk in Communities Study. Am. J. Epidemiol. 158 (12), 1171–1181 (2003).
87. Truelsen T, Prescott E, Lange P, Schnohr P, Boysen G. Lung function and risk of fatal and non-fatal stroke. The Copenhagen City Heart Study. Int. J. Epidemiol. 30 (1), 145–151 (2001).
88. 1. A new risk factor for coronary heart disease mortality. Am. J. Respir. Crit. Care Med. 151 (2 Pt 1), 390–398 (1995).
89. National Center for Health Statistics. Plan and operation of the third national health and nutrition examination survey, 1988–1994. Hyattsville, MD, NCHS, U.S. Department of Health and Human Services. Vital Health Statistics 1 (32), (1994)
90. Sin DD, Man SF. Chronic obstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortality. Proc. Am. Thorac. Soc. 2 (1), 8–11 (2005).
91. Curkendall SM, Deluise C, Jones JK et al. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann. Epidemiol. 16 (1), 63–70 (2006).
92. Ross R. Atherosclerosis – an inflammatory disease. N. Engl. J. Med. 340 (2), 115–126 (1999).
93. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 105 (9), 1135–1143 (2002).
94. Davies MJ, Gordon JL, Gearing AJ et al. The expression of the adhesion molecules ICAM-1, VCAM-1, PECAM, and E-selectin in human atherosclerosis. J. Pathol. 171 (3), 223–229 (1993).
95. Rifai N, Ridker PM. High-sensitivity C-reactive protein: a novel and promising marker of coronary heart disease. Clin. Chem. 47 (3), 403–411 (2001).
96. Man SF, Connett JE, Anthonisen NR, Wise RA, Tashkin DP, Sin DD. C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease. Thorax 61 (10), 849–853 (2006).
97. Rutten FH, Cramer MJ, Grobbee DE et al. Unrecognized heart failure in elderly patients with stable chronic obstructive pulmonary disease. Eur. Heart J. 18, 1887–1894 (2005).
98. Olivetti G, Abbi R, Quaini F et al. Apoptosis in the failing human heart. N. Engl. J. Med. 336 (16), 1131–1141 (1997).
99. Sekine Y, Kesler KA, Behnia M, Brooks-Brunn J, Sekine E, Brown JW. COPD may increase the incidence of refractory supraventricular arrhythmias following pulmonary resection for non-small cell lung cancer. Chest 120 (6), 1783–1790 (2001).
100. Engelmann MD, Svendsen JH. Inflammation in the genesis and perpetuation of atrial fibrillation. Eur. Heart J. 26 (20), 2083–2092 (2005).
101. Dernellis J, Panaretou M. C-reactive protein and paroxysmal atrial fibrillation: evidence of the implication of an inflammatory process in paroxysmal atrial fibrillation. Acta Cardiol. 56 (6), 375–380 (2001).
102. Chung MK, Martin DO, Sprecher D et al. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation 104 (24), 2886–2891 (2001).
103. Engelen MP, Schols AM, Heidendal GA, Wouters EF. Dual-energy x-ray absorptiometry in the clinical evaluation of body composition and bone mineral density in patients with chronic obstructive pulmonary disease. Am. J. Clin. Nutr. 68 (6), 1298–1303 (1998).
104. Bolton CE, Ionescu AA, Shiels KM et al. Associated loss of fat-free mass and bone mineral density in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 170 (12), 1286–1293 (2004).
105. Iqbal F, Michaelson J, Thaler L, Rubin J, Roman J, Nanes MS. Declining bone mass in men with chronic pulmonary disease: contribution of glucocorticoid treatment, body mass index, and gonadal function. Chest 116 (6), 1616–1624 (1999).
106. De Vries F, van Staa TP, Bracke MS, Cooper C, Leufkens HG, Lammers JW. Severity of obstructive airway disease and risk of osteoporotic fracture. Eur. Respir. J. 25 (5), 879–884 (2005).
107. Clowes JA, Riggs BL, Khosla S. The role of the immune system in the pathophysiology of osteoporosis. Immunol. Rev. 208, 207–227 (2005).
108. Bertolini DR, Nedwin GE, Bringman TS, Smith DD, Mundy GR. Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature 319 (6053), 516–518 (1986).
109. Dinh-Xuan AT, Higenbottam TW, Clelland CA et al. Impairment of endothelium-dependent pulmonary-artery relaxation in chronic obstructive lung disease. N. Engl. J. Med. 324 (22), 1539–1547 (1991).
110. Baudouin SV, Bott J, Ward A, Deane C, Moxham J. Short term effect of oxygen on renal haemodynamics in patients with hypoxaemic chronic obstructive airways disease. Thorax 47 (7), 550–554 (1992).
111. Howes TQ, Deane CR, Levin GE, Baudouin SV, Moxham J. The effects of oxygen and dopamine on renal and aortic blood flow in chronic obstructive pulmonary disease with hypoxemia and hypercapnia. Am. J. Respir. Crit. Care Med. 151 (2 Pt 1), 378–383 (1995).
112. Ferri C, Bellini C, De Angelis C et al. Circulating endothelin-1 concentrations in patients with chronic hypoxia. J. Clin. Pathol. 48 (6), 519–524 (1995).
113. Sofia M, Maniscalco M, Celentano L et al. Abnormalities of renal endothelin during acute exacerbation in chronic obstructive pulmonary disease. Pulm. Pharmacol. Ther. 14 (4), 321–327 (2001).
114. Barbera JA, Peinado VI, Santos S. Pulmonary hypertension in chronic obstructive pulmonary disease. Eur. Respir. J. 21 (5), 892–905 (2003).
115. Mathur R, Cox IJ, Oatridge A, Shephard DT, Shaw RJ, Taylor-Robinson SD. Cerebral bioenergetics in stable chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 160 (6), 1994–1999 (1999).
116. Hochachka PW, Clark CM, Brown WD et al. The brain at high altitude: hypometabolism as a defense against chronic hypoxia? J. Cereb. Blood Flow Metab. 14 (4), 671–679 (1994).
117. Borak J, Sliwinski P, Piasecki Z, Zielinski J. Psychological status of COPD patients on long term oxygen therapy. Eur. Respir. J. 4 (1), 59–62 (1991).
118. Light RW, Merrill EJ, Despars JA, Gordon GH, Mutalipassi LR. Prevalence of depression and anxiety in patients with COPD. Relationship to functional capacity. Chest 87 (1), 35–38 (1985).
119. Wagena EJ, Huibers MJ, Van Schayck CP. Antidepressants in the treatment of patients with COPD: possible associations between smoking cigarettes, COPD and depression. Thorax 56 (8), A587 –A588 (2001).
120. Connor TJ, Leonard BE. Depression, stress and immunological activation: the role of cytokines in depressive disorders. Life Sci. 62 (7), 583–606 (1998).
121. Pollak Y, Yirmiya R. Cytokine-induced changes in mood and behaviour: implications for ‘depression due to a general medical condition’, immunotherapy and antidepressive treatment. Int. J. Neuropsychopharmacol. 5 (4), 389–399 (2002).
122. Anisman H, Hayley S, Turrin N, Merali Z. Cytokines as a stressor: implications for depressive illness. Int. J. Neuropsychopharmacol. 5 (4), 357–373 (2002).
123. Appenzeller O, Parks RD, MacGee J. Peripheral neuropathy in chronic disease of the respiratory tract. Am. J. Med. 44 (6), 873–880 (1968).
124. Narayan M, Ferranti R. Nerve conduction impairment in patients with respiratory insufficiency and severe chronic hypoxemia. Arch. Phys. Med. Rehabil. 59 (4), 188–192 (1978).
125. Valli G, Barbieri S, Sergi P, Fayoumi Z, Berardinelli P. Evidence of motor neuron involvement in chronic respiratory insufficiency. J. Neurol. Neurosurg. Psychiatry 47 (10), 1117–1121 (1984).
126. Dyck PJ. Hypoxic neuropathy: does hypoxia play a role in diabetic neuropathy? The 1988 Robert Wartenberg lecture. Neurology 39 (1), 111–118 (1989).
127. Stewart AG, Waterhouse JC, Howard P. Cardiovascular autonomic nerve function in patients with hypoxaemic chronic obstructive pulmonary disease. Eur. Respir. J. 4 (10), 1207–1214 (1991).
128. Stewart AG, Marsh F, Waterhouse JC, Howard P. Autonomic nerve dysfunction in COPD as assessed by the acetylcholine sweat-spot test. Eur. Respir. J. 7 (6), 1090–1095 (1994).
129. Vinik AI, Maser RE, Mitchell BD, Freeman R. Diabetic autonomic neuropathy. Diabetes Care 26 (5), 1553–1579 (2003).
130. Johnson RH, Robinson BJ. Mortality in alcoholics with autonomic neuropathy. J. Neurol. Neurosurg. Psychiatry 51 (4), 476–480 (1988).
131. Laghi F, Antonescu-Turcu A, Collins E, et al. Hypogonadism in men with chronic obstructive pulmonary disease: prevalence and quality of life. Am. J. Respir. Crit. Care Med. 171 (7), 728–733 (2005).
132. Creutzberg EC, Casaburi R. Endocrinological disturbances in chronic obstructive pulmonary disease. Eur. Respir. J. (Suppl. 46), S76 –S80 (2003).
133. Kamischke A, Kemper DE, Castel MA et al. Testosterone levels in men with chronic obstructive pulmonary disease with or without glucocorticoid therapy. Eur. Respir. J. 11 (1), 41–45 (1998).
134. Van Vliet M, Spruit MA, Verleden G et al. Hypogonadism, quadriceps weakness, and exercise intolerance in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 172 (9), 1105–1111 (2005).
135. Casaburi R, Goren S, Bhasin S. Substantial prevalence of low anabolic hormone levels in COPD patients undergoing rehabilitation. Am. J. Respir. Crit. Care Med. 153, A128 (1996).
136. Debigare R, Marquis K, Cote CH et al. Catabolic/anabolic balance and muscle wasting in patients with COPD. Chest 124 (1), 83–89 (2003).
137. Snyder PJ. Hypogonadism in elderly men: what to do until the evidence comes. N. Engl. J. Med. 350, 440–442 (2004).
138. Laghi F. Low testosterone in chronic obstructive pulmonary disease: does it really matter? Am. J. Respir. Crit. Care Med. 172 (9), 1069–1070 (2005).
139. Dimopoulou I, Ilias I, Mastorakos G, Mantzos E, Roussos C, Koutras DA. Effects of severity of chronic obstructive pulmonary disease on thyroid function. Metabolism 50 (12), 1397–1401 (2001).
140. Sin DD, Lacy P, York E, Man SF. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 170 (7), 760–765 (2004).
141. Macie C, Wooldrage K, Manfreda J, Anthonisen NR. Inhaled corticosteroids and mortality in COPD. Chest 130 (3), 640–646 (2006).
142. Huiart L, Ernst P, Ranouil X, Suissa S. Low-dose inhaled corticosteroids and the risk of acute myocardial infarction in COPD. Eur. Respir. J. 25 (4), 634–639 (2005).
143. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. Br. Med. J. 326 (7404), 1423 (2003).
144. Wierzbicki AS, Poston R, Ferro A. The lipid and non-lipid effects of statins. Pharmacol. Ther. 99 (1), 95–112 (2003).
145. Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J. Clin. Invest. 101 (12), 2711–2719 (1998).
146. Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator. Nat. Med. 6 (12) 1399–1402 (2000).
147. Aviram M, Rosenblat M, Bisgaier CL, Newton RS. Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation. Atherosclerosis 138 (2), 271–280 (1998).
148. Resch U, Tatzber F, Budinsky A, Sinzinger H. Reduction of oxidative stress and modulation of autoantibodies against modified low-density lipoprotein after rosuvastatin therapy. Br. J. Clin. Pharmacol. 61 (3), 262–274 (2006).
149. Frost FJ, Petersen H, Tollestrup K, Skipper B. Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. Chest 131 (4), 1006–1012 (2007).
150. Soyseth V, Brekke PH, Smith P, Omland T. Statin use is associated with reduced mortality in COPD. Eur. Respir. J. 29 (2), 279–283 (2007).
151. Mancini GB, Etminan M, Zhang B, Levesque LE, FitzGerald JM, Brophy JM. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J. Am. Coll. Cardiol. 47 (12), 2554–2560 (2006).
152. Global Initiative for Chronic Obstructive Pulmonary Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease, executive summary 2006. www.goldcopd.com.